Megestrol Acetate Oral Suspension
"For the first time, researchers have used national data to determine the incidence of the four major molecular subtypes of breast cancer by age, race/ethnicity, poverty level, and several other factors. These four subtypes respond differently to "...
Megestrol Acetate Oral Suspension
Megestrol Acetate Oral Suspension Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Megestrol acetate oral suspension contains a form of the female hormone progesterone and is used to treat anorexia, wasting (cachexia), or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Megestrol acetate oral suspension is available in generic form. Common side effects of megestrol acetate oral suspension include diarrhea, weight gain, changes in appetite, nausea, stomach upset, rash, impotence, touble sleeping (insomnia), mood swings, sweating, breakthrough menstrual bleeding or other changes in menstrual periods, decreased sexual ability/desire, high blood pressure, fever, and gas.
The recommended adult initial dosage of megestrol acetate oral suspension is 800 mg/day (20 mL/day). Megestrol acetate oral suspension may interact with other drugs. Tell your doctor all medications and supplements you use. Megestrol acetate should not be used during pregnancy. It may cause fetal harm. Because of the potential for adverse effects on a nursing baby, breastfeeding should be discontinued if megestrol acetate oral suspension is required.
Our megestrol acetate oral suspension Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Megestrol Acetate Oral Suspension FDA Prescribing Information: Side Effects
Clinical Adverse Events: Adverse events which occurred in at least 5% of patients in any arm of the two clinical efficacy trials and the open trial are listed below by treatment group. All patients listed had at least one post baseline visit during the 12 study weeks. These adverse events should be considered by the physician when prescribing megestrol acetate oral suspension.
% of Patients Reporting
|Open Label Trial
Adverse events which occurred in 1 to 3% of all patients enrolled in the two clinical efficacy trials with at least one follow-up visit during the first 12 weeks of the study are listed below by body system. Adverse events occurring less than 1% are not included. There were no significant differences between incidence of these events in patients treated with megestrol acetate and patients treated with placebo.
Hemic and Lymphatic System - leukopenia
Special Senses - amblyopia
Postmarketing - Postmarketing reports associated with megestrol acetate oral suspension included throm-boembolic phenomena including thrombophlebitis and pulmonary embolism and glucose intolerance (see WARNINGS and PRECAUTIONS sections).
Read the entire FDA prescribing information for Megestrol Acetate Oral Suspension (Megestrol Acetate Oral Suspension)
Additional Megestrol Acetate Oral Suspension Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find support and advances in treatment.